Skip to main content
Quest Diagnostics

Driving oncology cost savings with minimal residual disease testing

Minimal residual disease (MRD) testing is at the forefront of both improving patient outcomes for cancer patients, as well as promoting cost savings by helping to detect residual disease, guide adjunctive therapy, and avoid chemotherapy.

Complete the form to access a in-depth webinar discussion of the recent advancements in personalized diagnostics and the bottom-line impact it is having on patient care.

Access the webinar: Saving healthcare dollars with MRD testing

839

* indicates required

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.